Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Trimmed by Quattro Financial Advisors LLC

Quattro Financial Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 90.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 531 shares of the medical research company’s stock after selling 5,169 shares during the period. Thermo Fisher Scientific comprises approximately 28.7% of Quattro Financial Advisors LLC’s holdings, making the stock its 2nd largest position. Quattro Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $282,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TMO. Savant Capital LLC lifted its holdings in Thermo Fisher Scientific by 0.5% in the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 18 shares during the period. 1776 Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares during the period. Sugarloaf Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after purchasing an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton increased its holdings in Thermo Fisher Scientific by 3.7% in the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 19 shares during the last quarter. Finally, Tsfg LLC lifted its stake in Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Marc N. Casper sold 5,547 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMO. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. The Goldman Sachs Group increased their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Royal Bank of Canada lifted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Raymond James increased their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Price Performance

TMO traded down $6.49 during trading on Wednesday, hitting $548.06. 897,822 shares of the stock traded hands, compared to its average volume of 1,529,955. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The business has a 50 day moving average price of $571.67 and a 200 day moving average price of $526.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company has a market cap of $209.20 billion, a price-to-earnings ratio of 35.44, a PEG ratio of 2.34 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the company earned $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.